Aquestive Therapeutics, Inc.
AQST
$4.39
-$0.08-1.68%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -27.05% | -89.83% | -96.00% | -152.89% | -88.55% |
| Total Depreciation and Amortization | -18.57% | -22.54% | -44.79% | -48.03% | -46.33% |
| Total Amortization of Deferred Charges | -2.41% | 2.62% | 11.54% | 50.99% | 135.15% |
| Total Other Non-Cash Items | 33.40% | 10.45% | 34.40% | 33.56% | 37.61% |
| Change in Net Operating Assets | 137.11% | 222.37% | 89.80% | 72.03% | -68.16% |
| Cash from Operations | 10.12% | -46.63% | -47.47% | -101.32% | -90.68% |
| Capital Expenditure | -80.75% | -253.46% | -207.50% | -45.89% | 74.07% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -80.75% | -253.46% | -207.50% | -45.89% | 74.07% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -16.67% | -13.04% | 99.93% | 99.93% | 99.94% |
| Issuance of Common Stock | 270.83% | 22.20% | 16.84% | -76.63% | -76.32% |
| Repurchase of Common Stock | 44.79% | 20.35% | 21.82% | -10.47% | -1.67% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 40.00% | -120.00% | -100.20% | -100.20% | -100.12% |
| Cash from Financing | 284.02% | 22.76% | 16.90% | -77.60% | -76.30% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 258.52% | 4.09% | -3.41% | -143.50% | -138.85% |